Skip to main content
SpringerLink
Log in

Other Complications of Multiple Myeloma

  • Chapter
  • First Online:
Multiple Myeloma and Other Plasma Cell Neoplasms

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Acute renal failure (ARF) may manifest as first symptom leading to the diagnosis of MM or, much more frequently, develops during the course of the disease. Cast nephropathy is the most frequent renal pathology followed by amyloidosis, light-chain deposit disease, and rare other manifestations. In ARF, rapid diagnostic work-up and initiation of effective therapy is essential. Anemia—due to myeloma and/or therapy—is a frequent complication and the cause of impaired QoL. Erythropoietin therapy is recommended in patients with concomitant chemotherapy and Hb <10 g/dL. The use of red blood cell transfusions should be restricted to patients with severe symptomatic anemia not responding to erythropoietin or to those with need for rapid hemoglobin increase. Infections account for about 40% of overall mortality in MM. Prophylactic measures including vaccination, antiviral (in patients on proteasome inhibitors) and, in selected cases, antibiotic prophylaxis are recommended. In case of suspected infection and severe symptoms, antibiotic treatment should be started even before availability of diagnostic test results. Polyneuropathy (PNP) is manifest in about 20% of patients before the start of therapy. Thalidomide induces a sensory-motoric and bortezomib a sensory-symmetric, distal PNP. Prophylaxis is not available, but careful assessment of emerging symptoms is required to allow for timely dose reduction or treatment discontinuation. Bleeding is rare and often associated with hyperviscosity mandating effective myeloma therapy, and in specific cases, supplementation with coagulation factors. Prophylaxis of venous thromboembolism with aspirin in low and LMWH or coumarin in higher-risk patients is recommended during IMiD therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anaissie E (2011) Infection prophylaxis including vaccination for MM patients. International Myeloma Workshop (IMW), Paris

    Google Scholar 

  • Arvin A, Campadelli-Fiume G, Mocarski E et al (2007) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge

    Book  Google Scholar 

  • Badros AZ, Vij R, Martin T et al (2013) Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 27(8):1707–1714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bahlis NJ, Lazarus HM (2006) Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant 38(1):7–15

    Article  CAS  PubMed  Google Scholar 

  • Becker PS (2011) Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma. J Clin Oncol 29(7):783–786

    Article  CAS  PubMed  Google Scholar 

  • Beguin Y, Yerna M, Loo M et al (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82(4):648–653

    Article  CAS  PubMed  Google Scholar 

  • Beguin Y, Maertens J, De Prijck B et al (2013) Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 88(12):990–996

    Article  CAS  PubMed  Google Scholar 

  • Birgegard G, Gascon P, Ludwig H (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 77(5):378–386

    Article  PubMed  PubMed Central  Google Scholar 

  • Blade J, Sonneveld P, San Miguel JF et al (2008) Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8(6):352–355

    Article  CAS  PubMed  Google Scholar 

  • Blimark C, Holmberg E, Mellqvist UH et al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100(1):107–113

    Article  PubMed  PubMed Central  Google Scholar 

  • Boyle EM, Fouquet G, Manier S et al (2012) Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol 5(6):617–626

    Article  PubMed  Google Scholar 

  • Briani C, Torre CD, Campagnolo M et al (2013) Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. J Peripher Nerv Syst 18(1):19–24

    Article  CAS  PubMed  Google Scholar 

  • Bridoux F, Leung N, Hutchison CA et al (2015) Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87:698–711

    Article  CAS  PubMed  Google Scholar 

  • Bridoux F, Carron P-L, Pegourie B et al (2017) Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA 318(21):2099–2110. https://doi.org/10.1001/jama.2017.17924

    Article  PubMed  Google Scholar 

  • Burnette BL, Leung N, Rajkumar SV (2011) Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 364(24):2365–2366

    Article  CAS  PubMed  Google Scholar 

  • Chapel HM, Lee M, Hargreaves R et al (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343(8905):1059–1063

    Article  CAS  PubMed  Google Scholar 

  • Cook M, Hutchison C, Fifer L et al (2016) High cut-off haemodialysis (HCO-HD) does not improve outcomes in myeloma cast nephropathy: results of European trial of free light chain removal by extended haemodialysis in cast nephropathy (EULITE). Annual congress of the European Hematology Association, Abstract 270 https://learningcenter.ehaweb.org/eha/2016/21st/133257/mark.cook.high.cut-off.haemodialysis.28hcohd29.does.not.improve.outcomes.in.html?f=m3

  • Coppola A, Tufano A, Di Capua M et al (2011) Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945

    Article  PubMed  Google Scholar 

  • Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113(1):172–179

    Article  CAS  PubMed  Google Scholar 

  • De Stefano V, Za T, Rossi E (2014) Venous thromboembolism in multiple myeloma. Semin Thromb Hemost 40(3):338–347

    Article  PubMed  Google Scholar 

  • Delforge M, Blade J, Dimopoulos MA et al (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11(11):1086–1095

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos M, Alegre A, Stadtmauer EA et al (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116(16):3807–3814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dimopoulos MA, Kastritis E, Rosinol L et al (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22(8):1485–1493

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Richardson PG, Schlag R et al (2009a) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27(36):6086–6093

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Roussou M, Gavriatopoulou M et al (2009b) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 9(4):302–306

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Chen C, Spencer A et al (2009c) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147–2152

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Palumbo A, Attal M et al (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25(5):749–760

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Roussou M, Gkotzamanidou M et al (2013) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27(2):423–429

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Delimpasi S, Katodritou E et al (2014a) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25(1):195–200

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Leleu X, Palumbo A et al (2014b) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573–1585

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dimopoulos MA, Sonneveld P, Leung N et al (2016a) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557

    Article  PubMed  Google Scholar 

  • Dimopoulos MA, Moreau P, Palumbo A et al (2016b) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38

    Article  CAS  PubMed  Google Scholar 

  • Eleutherakis-Papaiakovou V, Bamias A, Gika D et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48(2):337–341

    Article  CAS  PubMed  Google Scholar 

  • Fakhouri F, Guerraoui H, Presne C et al (2004) Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 125(1):96–97

    Article  CAS  PubMed  Google Scholar 

  • Fermand JP, Bridoux F, Kyle RA et al (2013) How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122:3583–3590

    Article  CAS  PubMed  Google Scholar 

  • Gordon DS, Hearn EB, Spira TJ et al (1984) Phase I study of intravenous gamma globulin in multiple myeloma. Am J Med 76(3A):111–116

    Article  CAS  PubMed  Google Scholar 

  • Gorson KC, Ropper AH (1997) Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 63(2):163–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hainz N, Thomas S, Neubert K et al (2012) The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 120(2):e47–e58

    Article  CAS  PubMed  Google Scholar 

  • Hammond SP, Gagne LS, Stock SR et al (2012) Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. Clin Microbiol 50(10):3216–3221

    Article  Google Scholar 

  • Hargreaves RM, Lea JR, Griffiths H et al (1995) Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 48(3):260–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122(3):394–403

    Article  CAS  PubMed  Google Scholar 

  • Hutchison CA, Batuman V, Behrens J et al (2011) The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 8(1):43–51

    Article  PubMed  PubMed Central  Google Scholar 

  • Jagannath S, Barlogie B, Berenson JR et al (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103(6):1195–1200

    Article  CAS  PubMed  Google Scholar 

  • Jhaveri KD, Wanchoo R (2015) Carfilzomib-induced nephrotoxicity. Kidney Int 88(1):199–200

    Article  CAS  PubMed  Google Scholar 

  • Johnson WJ, Kyle RA, Pineda AA et al (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150(4):863–869

    Article  CAS  PubMed  Google Scholar 

  • Kastritis E, Anagnostopoulos A, Roussou M et al (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92(4):546–549

    Article  CAS  PubMed  Google Scholar 

  • Kastritis E, Terpos E, Dimopoulos MA (2013) Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother 14(11):1477–1495

    Article  CAS  PubMed  Google Scholar 

  • Khalafallah A, Maiwald M, Cox A et al (2010) Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents. Mediterr J Hematol Infect Dis 2(1):e2010005

    PubMed  PubMed Central  Google Scholar 

  • Knudsen LM, Hippe E, Hjorth M et al (1994) Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 53(4):207–212

    Article  CAS  PubMed  Google Scholar 

  • Kristinsson SY (2010) Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010:437–444

    PubMed  Google Scholar 

  • Kristinsson SY, Tang M, Pfeiffer RM et al (2012a) Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica 97(6):854–858

    Article  PubMed  PubMed Central  Google Scholar 

  • Kristinsson SY, Pfeiffer RM, Björkholm M et al (2012b) Thrombosis is associated with inferior survival in multiple myeloma. Haematologica 97(10):1603–1607. https://doi.org/10.3324/haematol.2012.064444

    Article  PubMed  PubMed Central  Google Scholar 

  • Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33

    Article  PubMed  Google Scholar 

  • Larocca A, Cavallo F, Bringhen S et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933–939

    Article  CAS  PubMed  Google Scholar 

  • Leboulleux M, Lelongt B, Mougenot B et al (1995) Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 48(1):72–79

    Article  CAS  PubMed  Google Scholar 

  • Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant; International Kidney and Monoclonal Gammopathy Research Group. Blood 120(22):4292–4295

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Fritz E, Kotzmann H, Höcker P et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322(24):1693–1699

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Adam Z, Hajek R et al (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28(30):4635–4641

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B (2014) International Myeloma Working Group recommendations for global myeloma care. Leukemia 28(5):981–992

    Google Scholar 

  • Ludwig H, Rauch E, Kuehr T et al (2015) Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica 100(3):385–391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ma CX, Lacy MQ, Rompala JF et al (2004) Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104(1):40–42

    Article  CAS  PubMed  Google Scholar 

  • Magrangeas F, Kuiper R, Avet-Loiseau H et al (2016) A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European multiple myeloma patients. Clin Cancer Res 22(17):4350–4355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martin TG (2013) Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park) 27(Suppl 3):4–10

    Google Scholar 

  • Morabito F, Gentile M, Ciolli S et al (2010) Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 84(3):223–228

    Article  CAS  PubMed  Google Scholar 

  • Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440

    Article  PubMed  Google Scholar 

  • Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634

    Article  CAS  PubMed  Google Scholar 

  • Musallam KM, Dahdaleh FS, Shamseddine AI et al (2009) Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 123(5):679–686

    Article  CAS  PubMed  Google Scholar 

  • Myatt EA, Westholm FA, Weiss DT et al (1994) Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 91(8):3034–3038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49(8):1211–1225

    Google Scholar 

  • Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20(10):2486–2494

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Davies F, Kropff M et al (2010) Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol 89(8):803–811

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Cavo M, Bringhen S et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29(8):986–993

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Rajkumar SV, San Miguel JF et al (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587–600

    Article  PubMed  PubMed Central  Google Scholar 

  • Pirani CL, Valeri A, D’Agati V et al (1987) Renal toxicity of nonsteroidal anti-inflammatory drugs. Contrib Nephrol 55:159–175

    Article  CAS  PubMed  Google Scholar 

  • Ponisch W, Moll B, Bourgeois M et al (2013) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 139(11):1937–1946

    Article  PubMed  Google Scholar 

  • Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548

    Article  PubMed  Google Scholar 

  • Richardson PG, Delforge M, Beksac M et al (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4):595–608

    Article  CAS  PubMed  Google Scholar 

  • Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996–5010

    Article  PubMed  Google Scholar 

  • Robertson JD, Nagesh K, Jowitt SN et al (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82(7):1261–1265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salonen J, Nikoskelainen J (1993) Lethal infections in patients with hematological malignancies. Eur J Haematol 51(2):102–108

    Article  CAS  PubMed  Google Scholar 

  • Sanders PW, Herrera GA, Kirk KA et al (1991) Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 64(4):527–537

    CAS  PubMed  Google Scholar 

  • San-Miguel JF, Richardson PG, Sonneveld P et al (2008) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22(4):842–849

    Article  CAS  PubMed  Google Scholar 

  • Scheid C, Sonneveld P, Schmidt-Wolf IG et al (2014) Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 99(1):148–154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schrijvers D (2011) Management of anemia in cancer patients: transfusions. Oncologist 16(Suppl 3):12–18

    Article  PubMed  Google Scholar 

  • Silvestris F, Cafforio P, Tucci M et al (2002) Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99(4):1305–1313

    Article  CAS  PubMed  Google Scholar 

  • Taylor C, Navarrete C, Contreras M (2008) Immunological complications of blood transfusion. Transfus Altern Transfus Med 10(3):112–126

    Article  Google Scholar 

  • Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA (2015) Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171:100–108

    Google Scholar 

  • Terpos E, Kleber M, Engelhardt M et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254–1266

    Article  PubMed  PubMed Central  Google Scholar 

  • Tonia T, Mettler A, Robert N et al (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407

    PubMed  Google Scholar 

  • Torra R, Blade J, Cases A et al (1995) Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91(4):854–859

    Article  CAS  PubMed  Google Scholar 

  • Tosi P, Zamagni E, Cellini C et al (2004) Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73(2):98–103

    Article  CAS  PubMed  Google Scholar 

  • Weinstein DA, Roy CN, Fleming MD et al (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100(10):3776–3781

    Article  CAS  PubMed  Google Scholar 

  • Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515

    Article  CAS  PubMed  Google Scholar 

  • Zangari M, Tricot G, Polavaram L et al (2010) Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28(1):132–135

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Cancer Research Institute, Vienna, Austria

    Heinz Ludwig

  2. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Meletios-Athanasios Dimopoulos & Evangelos Terpos

Authors
  1. Heinz Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meletios-Athanasios Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evangelos Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinz Ludwig .

Editor information

Editors and Affiliations

  1. School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Meletios A. Dimopoulos

  2. Service des Maladies du Sang, CHRU Lille Hôpital Claude Huriez, Lille, France

    Thierry Facon

  3. School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Evangelos Terpos

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ludwig, H., Dimopoulos, MA., Terpos, E. (2018). Other Complications of Multiple Myeloma. In: Dimopoulos, M., Facon, T., Terpos, E. (eds) Multiple Myeloma and Other Plasma Cell Neoplasms. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-25586-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-25586-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-25584-2

  • Online ISBN: 978-3-319-25586-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation